` 600535 (Tasly Pharmaceutical Group Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

600535
vs
Shanghai Composite

Over the past 12 months, has underperformed Shanghai Composite, delivering a return of 2% compared to the Shanghai Composite's 8% growth.

Stocks Performance
600535 vs Shanghai Composite

Loading

Performance Gap
600535 vs Shanghai Composite

Loading
600535
Shanghai Composite
Difference

Performance By Year
600535 vs Shanghai Composite

Loading
600535
Shanghai Composite
Add Stock

Competitors Performance
Tasly Pharmaceutical Group Co Ltd vs Peers

Shanghai Composite
600535
LLY
JNJ
NOVO B
ROG
Add Stock

Tasly Pharmaceutical Group Co Ltd
Glance View

Market Cap
22.6B CNY
Industry
Pharmaceuticals

In the heart of China's bustling pharmaceutical landscape lies Tasly Pharmaceutical Group Co Ltd, a company intricately blending traditional herbal wisdom with cutting-edge scientific innovation. Founded in 1994, this enterprise has carved a niche in the competitive world of healthcare by focusing on Traditional Chinese Medicine (TCM) while also expanding into chemical medicine and biological drugs. Tasly's ecosystem thrives on the research, development, manufacturing, and marketing of its diverse product portfolio, which includes patent medicines, herbal injections, and health supplements. The crown jewel in its product lineup is the Compound Danshen Dripping Pill, a herbal medicine aimed at cardiovascular ailments, a testament to the company's commitment to merging ancient remedies with modern health solutions. By establishing an extensive distribution network both domestically and internationally, Tasly ensures its unique offerings reach a wide audience, catering not only to China's growing appetite for health products but also tapping into global markets hungry for alternative medicine solutions. Tasly’s financial engine leverages its broad spectrum of offerings, driven by both consumer demand for TCM and the pharmaceutical industry's appetite for innovation. The company invests significantly in research and development, with a particular emphasis on internationalizing TCM and obtaining global recognition for its products through clinical trials and partnerships. Such strategic actions bolster its competitive edge, positioning Tasly as a leader in an industry where tradition and science converge. Revenue streams are further diversified by the company's health management services and a growing footprint in biotechnology, showcasing its adaptability and forward-thinking approach. This intricate ballet of innovation and tradition enables Tasly Pharmaceutical Group to not just survive but thrive in an industry characterized by rapid advancements and shifting consumer paradigms.

Intrinsic Value
18.57 CNY
Undervaluation 18%
Intrinsic Value
Price
Back to Top